302 related articles for article (PubMed ID: 32165440)
1. End Points for Clinical Trials in Primary Hyperoxaluria.
Milliner DS; McGregor TL; Thompson A; Dehmel B; Knight J; Rosskamp R; Blank M; Yang S; Fargue S; Rumsby G; Groothoff J; Allain M; West M; Hollander K; Lowther WT; Lieske JC
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1056-1065. PubMed ID: 32165440
[TBL] [Abstract][Full Text] [Related]
2. End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
Langman CB; Assimos D; Blank M; Calle J; Grauer A; Kausz A; Milliner D; Nazzal L; Smith K; Tasian G; Thompson A; Wood KD; Worcester E; Yang S; Malley MA; Knauf F; Lieske JC;
Clin J Am Soc Nephrol; 2023 Dec; 18(12):1637-1644. PubMed ID: 37342976
[TBL] [Abstract][Full Text] [Related]
3. Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.
Singh P; Vaughan LE; Schulte PJ; Sas DJ; Milliner DS; Lieske JC
Am J Kidney Dis; 2022 Sep; 80(3):373-382. PubMed ID: 35306035
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.
Bollée G; Cochat P; Daudon M
Can J Kidney Health Dis; 2015; 2():31. PubMed ID: 26380104
[TBL] [Abstract][Full Text] [Related]
5. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
6. Renal transplantation in primary hyperoxaluria.
Watts RW; Morgan SH; Mansell MA; Purkiss P
Ann Acad Med Singap; 1987 Apr; 16(2):337-9. PubMed ID: 3318661
[TBL] [Abstract][Full Text] [Related]
7. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
Milliner D; Hoppe B; Groothoff J
Urolithiasis; 2018 Aug; 46(4):313-323. PubMed ID: 28718073
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D
Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
[TBL] [Abstract][Full Text] [Related]
9. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.
Hillebrand P; Hoppe B
Pediatr Nephrol; 2020 Jul; 35(7):1227-1233. PubMed ID: 32274573
[TBL] [Abstract][Full Text] [Related]
10. Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria.
Wang X; Bhutani G; Vaughan LE; Enders FT; Haskic Z; Milliner D; Lieske JC;
BMC Nephrol; 2020 Apr; 21(1):133. PubMed ID: 32293313
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.
Arnous MG; Vaughan L; Mehta RA; Schulte PJ; Lieske JC; Milliner DS
J Urol; 2023 Jun; 209(6):1141-1150. PubMed ID: 36888927
[TBL] [Abstract][Full Text] [Related]
12. Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort.
Shah RJ; Vaughan LE; Enders FT; Milliner DS; Lieske JC
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443777
[TBL] [Abstract][Full Text] [Related]
13. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria.
Tang X; Bergstralh EJ; Mehta RA; Vrtiska TJ; Milliner DS; Lieske JC
Kidney Int; 2015 Mar; 87(3):623-31. PubMed ID: 25229337
[TBL] [Abstract][Full Text] [Related]
14. Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.
Milliner DS; Cochat P; Hulton SA; Harambat J; Banos A; Dehmel B; Lindner E
Pediatr Nephrol; 2021 Jul; 36(7):1785-1793. PubMed ID: 33515281
[TBL] [Abstract][Full Text] [Related]
15. Estimating health state utilities in primary hyperoxaluria type 1: a valuation study.
de Freitas HM; Danese D; Hubig L; Lloyd A; Lombardelli S
J Med Econ; 2023; 26(1):386-393. PubMed ID: 36852648
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.
Zhao F; Bergstralh EJ; Mehta RA; Vaughan LE; Olson JB; Seide BM; Meek AM; Cogal AG; Lieske JC; Milliner DS;
Clin J Am Soc Nephrol; 2016 Jan; 11(1):119-26. PubMed ID: 26656319
[TBL] [Abstract][Full Text] [Related]
17. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
18. Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure.
Raju DL; Cantarovich M; Brisson ML; Tchervenkov J; Lipman ML
Am J Kidney Dis; 2008 Jan; 51(1):e1-5. PubMed ID: 18155525
[TBL] [Abstract][Full Text] [Related]
19. Primary hyperoxaluria: a rare but important cause of nephrolithiasis.
Wong PN; Tong GM; Lo KY; Mak SK; Law EL; Wong AK
Hong Kong Med J; 2002 Jun; 8(3):202-6. PubMed ID: 12055367
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
Demoulin N; Aydin S; Gillion V; Morelle J; Jadoul M
Am J Kidney Dis; 2022 May; 79(5):717-727. PubMed ID: 34508834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
